NEW ORAL DRUGS USED FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS

Abstract

Type two diabetes is considered one of the biggest diseases in the world and, in this context, there is a need for research and development of new drugs that are more effective in controlling glycemia and with fewer adverse effects. Despite the large number of pharmacological combinations, some individuals have observed some regularity in the control of diabetes. In recent years, the pharmaceutical industry has introduced new types of drugs of extreme importance to individuals. In recent years, peptidase 4 (DPP-4) inhibitors and, more recently, sodium/glucose cotransporter two (SGLT-2) inhibitors. These drugs offer greater convenience in glycemic control and have shown a low incidence of hypoglycemia, with adverse effects, although some frequency has been reported with other drugs. It was found that patients treated with SGLT-2 inhibitors were less likely to experience this effect and had a significant increase in weight loss and high blood pressure control.